Table 1.
Review of ibrutinib therapy for patients with LPD and CNS involvement.
| Ref. | Age | Sex | Diagnosis | Prior lines | CNS therapy | FU | Response | DOR | Toxicity |
|---|---|---|---|---|---|---|---|---|---|
| [11] | 61 | M | MCL | 3 | Ibrutinib 560 mg | 12 m | CR | Ongoing | None |
| [11] | 62 | M | MCL | 2 | Ibrutinib 560 mg | 9 m | CR | Ongoing | None |
| [11] | 77 | F | MCL | 2 | Ibrutinib 560 mg | 2 m | PR | Ongoing | None |
| [12] | 54 | M | MCL | 1 | HD-MTX and HiDAC + Ibrutinib 560 mg/d | 4 m | PR | 4 m | Bruising |
| [12] | 55 | M | MCL | 1 | Ibrutinib 560 mg MP 500 mg 4 d | 5 m | PR | 4 m | None |
| [12] | 65 | M | MCL | 1 | Ibrutinib 560 mg Dexamethasone IT Cytarabine | 4 m | CR | Ongoing | None |
| [12] | 58 | M | MCL | 1 | Ibrutinib 560 mg | 5 m | PR | Ongoing | None |
| [12] | 57 | M | MCL | 1 | HD-MTX Ibrutinib 560 mg |
1 w | Transient PR | 6 d | None |
| [13] | 58 | M | CLL | 8 | HiDAC, MTX, oxaliplatin, R- monotherapy, IT-CT, Iv immunoglobulins → Ibrutinib 420 mg/d | 9 m | CR | 9 m | Atrial fibrillation → death (stroke) |
| [13] | 65 | M | CLL | 4 | 14 m | CR | Ongoing | None | |
| [13] | 63 | M | CLL | 2 | 8 m | CR | Ongoing | None | |
| [13] | 68 | F | CLL | 0 | 9 m | CR | Ongoing | None | |
| [14] | 66 | M | CLL | 0 | Ibrutinib 420 mg/d | 8 m | CR | Ongoing | None |
| [15] | 72 | M | WM/BNS | 1 | R, HD-MTX IT liposomal cytarabine → Ibrutinib 420 mg/d |
6 m | CR | Ongoing | None |
| [15] | 56 | M | WM/BNS | 1 | R-HiDAC → Ibrutinib | 6 m | CR | Ongoing | None |
DOR: duration of response; MP: methylprednisolone; HD-MTX: high-dose methotrexate; HiDAC: high-dose ARA-C; IT-CT: intrathecal chemotherapy; m: months; w: week; d: days.